Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israel’s Teva Pharm Unlikely to Reach Deals to Co-Produce Vaccines: CEO
Error: Contact form not found.
by Reuters and Algemeiner Staff
A Teva building in Jerusalem, Israel, Dec. 14, 2017. Photo: Reuters / Ammar Awad.
Israel’s Teva Pharmaceutical Industries is not likely to reach deals with COVID vaccine makers to co-produce the vaccines although discussions are still ongoing, chief executive Kare Schultz told Reuters.
Schultz said Teva — the world’s largest generic drugmaker — offered to co-produce the vaccines in both Israel and Europe, where the company has capacity, to help with global supply.
“But we’ve not been able to reach a firm agreement with any company,” he said. “It’s not for our lack of wanting to do it but the key players that have actually been successful in developing the vaccines that have come to the market have found other partners or their own internal capacity.”
He did not name the companies.
“It’s probably pretty much done (but) we can’t rule it out,” Schultz said. “We’re still in discussion with some of the companies, and we’re still willing to do it if we can help.”
